Paola Queirolo

Associazione Italiana Di Oncologia Medica — Italy

Medicine · Health Sciences

67h-index18.5kcitations596works5.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(230), Melanoma and MAPK Pathways(145), Cutaneous Melanoma Detection and Management(137), CAR-T cell therapy research(120), Immunotherapy and Immune Responses(98)

Publications592 total

UNCONVENTIONAL PATTERN OF RESPONSE IN A METASTATIC MELANOMA PATIENT TREATED WITH IPILIMUMAB.
EuroMediterranean Biomedical Journal·2026Open Access
SOLAR RADIATION AS A RISK FACTOR FOR CUTANEOUS MELANOMA: REVIEW
EuroMediterranean Biomedical Journal·2026· 1 citedOpen Access
MALIGNANT MELANOMA ARISING IN A SPECKLED LENTIGINOUS NEVUS.
EuroMediterranean Biomedical Journal·2026· 1 citedOpen Access
COMPLETE RESPONSE OF CUTANEOUS METASTASIS IN A MELANOMA PATIENT TREATED WITH IPILIMUMAB.
EuroMediterranean Biomedical Journal·2026· 1 citedOpen Access
High BRAF variant allele frequency predicts poor outcomes in metastatic melanoma patients treated with BRAF/MEK inhibitors
Journal of Translational Medicine·2025Open Access
Supplementary Figure S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S2 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S4 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S9 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S10 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S5 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Methods S1 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Figure S3 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S11 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
Supplementary Table S6 from Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
2025Open Access
page 1 of 30Next →

Frequent Co-authors

Paolo A. Ascierto(27), Michele Maio(18), Michele Del Vecchio(17), Vanna Chiarion‐Sileni(16), Mario Mandalà(14), Francesco Spagnolo(11), Anna Maria Di Giacomo(10), Pier Francesco Ferrucci(10), Paolo Marchetti(10), Dirk Schadendorf(9), Ester Simeone(9), Alessandro Testori(9), Michele Guida(9), Piotr Rutkowski(8), Paola Ghiorzo(8), Ana Arance(7), James Larkin(7), Jacopo Pigozzo(7), Helen Gogas(6), Georgina V. Long(6)